Renal sympathetic denervation improves physical and mental health in resistant hypertension

August 27, 2012

Renal sympathetic denervation improves anxiety, depression, quality of life and stress in patients with resistant hypertension, according to research presented at ESC Congress 2012 by Dr Denise Fischer from Saarland University Hospital.

Arterial hypertension is often associated with several psychological comorbidities, such as and panic disorders, leading to impaired quality of life. Catheter-based renal sympathetic (RDN) is a novel treatment option for patients with resistant hypertension and has been shown to reduce local and whole-body sympathetic activity and blood pressure (BP).

The aim of the present study was to analyze quality of life, arousal level, anxiety and depression, sleeping quality, intensity of headache and stress tolerance in patients with resistant hypertension before and after RDN.

RDN was performed in 173 patients with resistant hypertension (BP 174/88±23/13mmHg and taking a median of 5 ) aged 63±10 years (53% male). Psychological status, intensity of headache, sleeping quality and were documented before and 3 months after RDN.

Patients rated their physical and mental state and arousal level on a 0-100% scale. Stress was induced by a multi tasking situation (Determination Task) and the total number of correct reactions, omissions and commission errors (responding to stimuli where it is not required) were recorded. Assessments were made of depression and anxiety using the Hospital Scale (HADS) and of quality of life using the Short Form-12 (SF-12). Insomnia and the level of regeneration achieved during sleep were assessed using a 0-100% scale and intensity of headache was measured by a visual analogous scale (VAS).

Three months after RDN was performed, office blood pressure decreased by 17/7 mmHg (p<0.01). In addition patients showed more correct reactions (p<0.0001) and less errors (p<0.05) in the multi tasking situation (Figure A shows the percentile rank (PR) score; the average percentile is 50%). Patients reported improvements in their physical state (from 55.6% to 67.2%; p<0.01), mental state (from 51.6% to 68.4%; p<0.05) and quality of life (p<0.05) (Figure B). Anxiety (p<0.0001) and depression (p<0.0001) scores decreased (Figure C). Arousal level was reduced from 49.9% to 38.9% (p<0.0001).

At baseline 32.2% of patients suffered from sleeping disorders and 60% suffered from headaches. Three months after RDN, sleeping quality improved (p<0.0001) and the intensity of headache decreased (p<0.0001) (Figure D).

"In patients with resistant hypertension overactivity of the sympathetic nervous system causes hyperarousal, leading to higher anxiety and stress levels," said Dr Fischer. "Renal denervation reduces office blood pressure and resting heart rate and does not impair psychological processes."

She added: "Renal denervation may have a positive effect on psychological processes, stress perception and processing as well as quality of life. It improves sleeping quality and may reduce the intensity of headache."

Future research should investigate long term effects of RDN on psychological processes, quality of life, rehospitalisation and mortality rates in a larger cohort of patients.

Explore further: Renal denervation treats resistant hypertension in real world patient populations

Related Stories

Renal denervation treats resistant hypertension in real world patient populations

August 27, 2012
Renal denervation successfully treats patients with resistant hypertension in real world patient populations, according to a study presented at ESC Congress 2012. The findings were presented by Dr Darren Mylotte from France.

Simple procedure lowers blood pressure in kidney disease patients

May 17, 2012
Disrupting certain nerves in the kidneys can safely and effectively lower blood pressure in patients with chronic kidney disease (CKD) and hypertension, according to a study appearing in an upcoming issue of the Journal of ...

Study tests new therapy for treatment-resistant hypertension

June 28, 2012
(Medical Xpress) -- Treatment-resistant hypertension affects nearly 6 million Americans and another 94 million people worldwide and is associated with increased cardiovascular risk, including stroke and heart attack, as well ...

Renal denervation gives better outcomes than drugs in advanced heart failure

August 27, 2012
Renal denervation leads to better outcomes than standard drug treatment in patients with advanced heart failure, according to research presented at ESC Congress 2012. The results of the Olomouc I pilot study were presented ...

Comorbidities are common in patients with COPD

May 21, 2012
The majority of patients with chronic obstructive pulmonary disease (COPD) referred for pulmonary rehabilitation have multiple extra-pulmonary comorbidities, according to a new study from the Netherlands.

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.